MLN-519. Millennium/PAION

Curr Opin Investig Drugs. 2003 Mar;4(3):333-41.

Abstract

Millennium Pharmaceuticals Inc (formerly LeukoSite Inc) and PAION GmbH are developing MLN-519, a ubiquitin/proteasome enzyme inhibitor, for the potential treatment of inflammatory diseases and stroke. MLN-519 is currently undergoing phase I clinical trials in acute stroke and myocardial infarction, and is poised to enter phase II trials.

Publication types

  • Review

MeSH terms

  • Acetylcysteine* / adverse effects
  • Acetylcysteine* / analogs & derivatives
  • Acetylcysteine* / pharmacology
  • Acetylcysteine* / therapeutic use
  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal / adverse effects
  • Anti-Inflammatory Agents, Non-Steroidal / pharmacology
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Clinical Trials as Topic
  • Cysteine Endopeptidases
  • Enzyme Inhibitors* / adverse effects
  • Enzyme Inhibitors* / pharmacology
  • Enzyme Inhibitors* / therapeutic use
  • Humans
  • Inflammation / drug therapy
  • Multienzyme Complexes / antagonists & inhibitors
  • Myocardial Infarction / drug therapy
  • Neuroprotective Agents* / adverse effects
  • Neuroprotective Agents* / pharmacology
  • Neuroprotective Agents* / therapeutic use
  • Proteasome Endopeptidase Complex
  • Stroke / drug therapy
  • Ubiquitin / antagonists & inhibitors

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Enzyme Inhibitors
  • Multienzyme Complexes
  • Neuroprotective Agents
  • PS519
  • Ubiquitin
  • Cysteine Endopeptidases
  • Proteasome Endopeptidase Complex
  • Acetylcysteine